deltatrials

Endometrial serous adenocarcinoma Trials in New Britain, United States

Conditions / Endometrial serous adenocarcinoma / New Britain, United States

Endometrial serous adenocarcinoma is a medical condition with active clinical research programs worldwide.

12 total trials for this combination

Showing top 10 of 12 trials

Trials

NCT ID Title Status Phase
NCT01935973 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer COMPLETED PHASE1
NCT03660826 Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone ACTIVE_NOT_RECRUITING
NCT00807768 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer UNKNOWN PHASE3
NCT03914612 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer ACTIVE_NOT_RECRUITING
NCT01132820 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer COMPLETED PHASE2
NCT02315469 Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery COMPLETED
NCT02065687 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer UNKNOWN PHASE2/PHASE3
NCT00977574 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer ACTIVE_NOT_RECRUITING
NCT00942357 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer UNKNOWN PHASE3
NCT01210222 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer COMPLETED PHASE2

Related Pages